Machine learning models, particularly XGBoost and Random Forest, achieved superior predictive performance compared with conventional statistical approaches, while patient age emerged as the most influential predictor of malignancy.
Abstract
Early and accurate classification of melanoma is essential for improving patient outcomes and supporting clinical decision-making. Although numerous predictive models have been proposed, comparisons between classical statistical approaches and modern machine learning algorithms are often limited by heterogeneous analytical workflows and inconsistent validation strategies. This study aimed to compare the predictive performance of classical statistical and machine learning models for melanoma classification using a fully reproducible analytical framework. A retrospective observational study was conducted using the publicly available BCN20000 dermoscopic dataset from the ISIC Archive. After standardized data preprocessing, four routinely available clinical variables (age, sex, anatomical site and melanocytic status) were used to develop Logistic Regression, Generalized Additive Models, Random Forest and Extreme Gradient Boosting (XGBoost) classifiers. All models were trained and evaluated using the same stratified training/testing split, and their performance was assessed through discrimination, calibration and SHAP explainability analysis. Machine learning models, particularly XGBoost and Random Forest, achieved superior predictive performance compared with conventional statistical approaches, while patient age emerged as the most influential predictor of malignancy. The proposed framework provides a transparent and reproducible approach for objectively comparing predictive models and supports the development of accurate, interpretable, and reproducible clinical decision-support systems for melanoma classification.
Breast cancer remains one of the most commonly diagnosed malignancies worldwide, and timely, accurate discrimination between benign and malignant breast masses is critical to reducing unnecessary biopsies while ensuring early treatment of true malignancies. This study presents a comprehensive, methodologically rigorous...
R. Agarwal, Divyansh Mishra, R. Mishra· International Journal of Onc...· 0 citations
Cervical cancer remains one of the leading causes of cancer-related mortality among women worldwide, particularly in low- and middle-income countries where access to early screening and diagnosis is limited. Accurate prediction of cervical cancer threat using machine learning techniques can support early intervention,...
Agwu Joy Nneka, Ituma Chinagolum· International Journal of Sci...· 0 citations
A systematic study of computational complexity has been conducted, and the results show that the training and inference latency of logistic regression is significantly lower than that of random forests, indicating its potential suitability for future resource-constrained clinical decision-support investigations after e...
A. ur Rehman, Mohamed A. Akela, T. Alyas et al.· Journal of Computing & B...· 0 citations
Background: Breast cancer is the leading cause of cancer-related mortality in females, with 2.3 million new cases diagnosed annually. Machine learning (ML) algorithms have the potential to improve diagnostic accuracy through the analysis of high-dimensional data. However, the lack of standardized benchmarks across diff...
Ali A. Hamad, Naaman Omar· Charmo Journal of Natural Sc...· 0 citations
Breast Cancer (BC) is still one of the deadliest causes of death for women, and timely and precise diagnosis is essential for achieving better clinical results with the use of reliable machine learning-based decision support. All three models, namely the optimized Artificial Neural Network (ANN), Decision Tree (DT) and...
R. Akhtar, Nauman Khalid· International Journal of Inn...· 0 citations
Overall, the included studies demonstrated good discriminative performance, suggesting that machine learning-based models may support early identification of high-risk patients and facilitate personalised clinical decision-making.